Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neuroendocrine Tumor Grade 2: early-phase trial registry
2 of 4 indexed Neuroendocrine Tumor Grade 2 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Neuroendocrine Tumor Grade 2: 4 US clinical trials tracked, 2 recruiting.
Neuroendocrine Tumor Grade 2 is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is David Bushnell, running 1 of these trials.
Enrollment posture brief
Registry condition neuroendocrine-tumor-grade-2
OPEN 2 | RECR 50% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Neuroendocrine Tumor Grade 2 lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neuroendocrine Tumor Grade 2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neuroendocrine Tumor Grade 2 is recruiting above its size-band peers.
2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
University of Iowa
NCT06395402
CapTemY90 for Grade 2/3 NET Liver Metastases
Abramson Cancer Center at Penn Medicine
NCT04339036
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
David Bushnell
NCT06148636
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
Yusuf Menda
NCT05111509
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Neuroendocrine Tumor Grade 2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neuroendocrine Tumor Grade 2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neuroendocrine Tumor Grade 2 page
4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Neuroendocrine Tumor Grade 2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- David Bushnell sponsors the most Neuroendocrine Tumor Grade 2 trials on record, review their full trial history before evaluating a specific study. See David Bushnell's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neuroendocrine Tumor Grade 2 condition card totals 4 registered trials; most-linked intervention [203Pb] VMT-α-NET SPECT/CT; top US site state Iowa. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.